We are a global provider of best-in-class clinical development and comprehensive commercialization services to the biopharmaceutical industry. Visit us at the event: booth #1517. […]
How Important is Economic Evaluation in Healthcare Decision Making?
Tony Culyer presents the basic case for using cost-effectiveness evidence for investment and disinvestment decisions about health care technologies, in this article, based on a presentation given at the 2014 ISPOR 19th Annual International Meeting. See more here. (Source: Anthony Culyer, Health […]
Have You Seen These New Outcomes Research Books From ISPOR?
ISPOR outcomes research books are products of ISPOR Special Interest Groups (SIG). These books are excellent resources for health care outcomes researchers and decision makers. The following ISPOR books are available for purchase here. ISPOR Taxonomy of Patient Registries: Classification, […]
Health Care Cost, Quality and Outcomes: ISPOR Book of Terms
This ISPOR publication includes over 100 monographs covering over 400 terms used in health care delivery, management, and regulation, as well as health care outcomes research including clinical, economic, and quality-of-life research terms. Publication available here. […]
Therapeutic and Diagnostic Device Outcomes Research
This book informs: health outcomes researchers on the unique characteristics of therapeutic and diagnostic devices; medical device developers and researchers on the basic principles of clinical, economic; and patient-reported outcomes research for therapeutic and diagnostic […]
ISPOR Taxonomy of Patient Registries: Classification, Characteristics and Terms
This taxonomy describes the characteristics & classifications of patient registries and terms used in the design, development, implementation of registries, as well as the terms used in the analysis, reporting, and publishing of registry data. Each term includes a brief definition, a broader […]
Reliability and Validity of Data Sources for Outcomes Research & Disease and Health Management Programs
The ISPOR Health and Disease Management Special Interest Group developed this handbook as resource to improve the evidence base in health care studies with the ultimate goal of better patient outcomes and lower health care costs. This handbook provides an overview of the sources of data for […]
How Well Do You Understand The Fundamentals Of Economic Evaluation?
This discussion paper is intended to be a starting point for health system and policy researchers who wish to understand some of the fundamentals of economic evaluation and its application in complex interventions. Produced in partnership with CIHR Institute of Health Services and Policy Research, […]
Check Out The Health Economics and Decision Science (HEDS) Winter Newsletter
Keep up to date on HEDS activities with the recently released Health Economics and Decision Science Winter Newsletter. A sneak preview of another Massive Open Online Course (MOOC), Alcohol Pricing, Online Telemonitoring Model and more, see here. (Source: The University Of Sheffield). […]
New Journal Targets Real-World Data, Health Outcomes, Healthcare Decision-Making & Big Data
Drugs - Real World Outcomes targets research involving the use of real-world data to evaluate health outcomes and inform healthcare decision-making, with a particular focus on healthcare-related 'big data'. Drugs-Real World Outcomes has a broad scope, encompassing studies investigating drug […]
Assess Health Care Research Studies With This Interactive Questionnaire
The 'Assessing the Evidence for Health Care Decision Makers' is an interactive questionnaire for users of evidence to assess health care research studies used in health technology assessments and/or drug formulary decisions. More information available here. (Source: Assessing the Evidence). […]
The Costs of Specialised Care
Chris Bojke, Katja Grasic, Andrew Street Patients requiring specialised care are usually treated by specialist teams with particular expertise and equipment. Concentrating services in this way should be cost-effective but there is concern that national tariffs might fail to fully reflect […]
Use of Multi-Criteria Decision Analysis (MCDA) in Health Care Decisions
Read more here. […]
Health Care Decisions in Europe – Early Scientific Advice
Read here. […]
ISPOR Global Health Care Systems Road Map
See here. […]
Pharmacoeconomic Guidelines Around The World
See here. […]
Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
ISPOR TASK FORCE REPORT available here. […]
Global Health Care Systems Road Map
More information here. […]
Pharmecoeconomics Guidelines Around The World
More information here. […]
Pharmacoeconomic Guidelines-Sample
More information here. […]
Pharmacoeconomic Guidelines Around The World
Pharmacoeconomic (PE) guidelines can be used as a standard for preparation of studies to be included in application for reimbursement, a guide for designing and conducting a study, or a template for evaluating the economic study reports. More information available here. (Source: ISPOR) […]
Should NICE Lower Cost-Per-QALY Threshold?
NICE Lower Threshold Research – What Does Ulf Stagginus Have To Say About?
Ulf tells it like it is here! […]
The Evolution of Product Evaluation
Multi-National Retrospective Chart Review Studies: Application of Methodology to Evaluations of Burden of Illness and Drug Utilization and Safety
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
Economic evaluations of health interventions pose a particular challenge for reporting. There is also a need to consolidate and update existing guidelines and promote their use in a user friendly manner. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement is an attempt […]
Poor Health Costs U.S. Economy $576 Billion
The upcoming presidential election hinges on health care and the economy. IBI evaluated how these two issues intersect, by using its Full Cost Estimator (FCE) to calculate the impact of poor health on the economy. Our data show that poor health costs the U.S. economy $576 billion per year, with 39 […]
Valuing Diagnostics: Do We Need Different Metrics? PPT by M. Sculpher
Presentation at ISPOR Europe, Nov. 2011, by Mark Sculpher, PhD, Professor of Health Economics, University of York, UK […]
Using Methods of Experimental Economics to Investigate Individual Determinants of Adherence and Implications for Mechanisms to Nudge Patients’ Behavior
Behnud Mir Djawadi, Research Associate, Department of Management, University of Paderborn, Paderborn, Germany; René Fahr, Full Professor, Department of Management, University of Paderborn, Paderborn, Germany; Florian Turk, Global Head, Health Economics & Outcomes Research, Critical Care Business […]
Using Net Benefits to Report Cost-Effectiveness Results, PPT by K. O
Presentation at ISPOR Europe, Nov. 2011, by Ken O'Day, PhD, Director, Xcenda, LLC, Palm Harbor, FL, USA; Denise Globe, PhD, Senior Director, Global Health Outcomes Strategy and Research, Allergan, LLC, Irvine, CA, USA […]
